Type 2 diabetes patients who received triweekly degludec dosing had inferior glycemic control and a higher risk of hypoglycemia within the first 24 hours compared with those who were on once-daily glargine, two late-stage trials indicated. Evidence does not support the use of a three-times-a-week dosing of insulin degludec, researchers concluded. The findings were published in the Lancet Diabetes-Endocrinology.

Related Summaries